145 related articles for article (PubMed ID: 37195312)
21. Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy.
Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
Int J Clin Oncol; 2015 Feb; 20(1):176-81. PubMed ID: 24771079
[TBL] [Abstract][Full Text] [Related]
22. A solitary positive prostate cancer biopsy does not predict a unilateral lesion in radical prostatectomy specimens.
Koie T; Mitsuzuka K; Narita S; Yoneyama T; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C
Scand J Urol; 2015 Apr; 49(2):103-7. PubMed ID: 25165894
[TBL] [Abstract][Full Text] [Related]
23. Prostate health index density predicts aggressive pathological outcomes after radical prostatectomy in Taiwanese patients.
Huang YP; Lin TP; Cheng WM; Wei TC; Huang IS; Fan YH; Lin CC; Huang EYH; Chung HJ; Kuo JY; Wu HHH; Lu SH; Chang YH; Lin ATL; Huang WJS
J Chin Med Assoc; 2019 Nov; 82(11):835-839. PubMed ID: 31425303
[TBL] [Abstract][Full Text] [Related]
24. Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer.
Preisser F; Marchioni M; Nazzani S; Bandini M; Tian Z; Saad F; Pompe RS; Briganti A; Budäus L; Montorsi F; Huland H; Graefen M; Tilki D; Karakiewicz PI
Eur Urol Oncol; 2018 Jun; 1(2):160-168. PubMed ID: 31100241
[TBL] [Abstract][Full Text] [Related]
25. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.
Özsoy M; D'Andrea D; Moschini M; Foerster B; Abufaraj M; Mathieu R; Briganti A; Karakiewicz PI; Roupret M; Seitz C; Czech AK; Susani M; Shariat SF
Urol Oncol; 2018 Apr; 36(4):158.e1-158.e6. PubMed ID: 29288003
[TBL] [Abstract][Full Text] [Related]
26. Active surveillance for localized prostate cancer: update of a prospective single-center cohort.
Thostrup M; Thomsen FB; Iversen P; Brasso K
Scand J Urol; 2018 Feb; 52(1):14-19. PubMed ID: 28958194
[TBL] [Abstract][Full Text] [Related]
27. Prostate cancer grade migration and facility-level treatment trends for grade group 1 disease.
Borregales LD; Tzeng M; Ramaswamy A; Gu X; Davuluri M; Nagar H; Hu JC
JNCI Cancer Spectr; 2023 Mar; 7(2):. PubMed ID: 36840651
[TBL] [Abstract][Full Text] [Related]
28. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
[TBL] [Abstract][Full Text] [Related]
29. Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations.
Leyh-Bannurah SR; Karakiewicz PI; Pompe RS; Preisser F; Zaffuto E; Dell'Oglio P; Briganti A; Nafez O; Fisch M; Steuber T; Graefen M; Budäus L
World J Urol; 2019 Mar; 37(3):469-479. PubMed ID: 29992380
[TBL] [Abstract][Full Text] [Related]
30. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study.
Stattin P; Sandin F; Thomsen FB; Garmo H; Robinson D; Lissbrant IF; Jonsson H; Bratt O
Eur Urol; 2017 Jul; 72(1):125-134. PubMed ID: 27481175
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
[TBL] [Abstract][Full Text] [Related]
32. Preoperative prostate health index predicts poor pathologic outcomes of radical prostatectomy in patients with biopsy-detected low-risk patients prostate cancer: results from a Chinese prospective cohort.
Tang B; Han CT; Lu XL; Wan FN; Zhang CZ; Zhu Y; Ye DW
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):64-70. PubMed ID: 29213105
[TBL] [Abstract][Full Text] [Related]
33. The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients.
Bandini M; Preisser F; Nazzani S; Marchioni M; Tian Z; Mazzone E; Graefen M; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
Eur Urol Oncol; 2018 Aug; 1(3):215-222. PubMed ID: 31102624
[TBL] [Abstract][Full Text] [Related]
34. The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes.
Mazzone E; Preisser F; Nazzani S; Tian Z; Bandini M; Gandaglia G; Fossati N; Montorsi F; Graefen M; Shariat SF; Saad F; Briganti A; Karakiewicz PI
Eur Urol Oncol; 2019 Sep; 2(5):541-548. PubMed ID: 31411992
[TBL] [Abstract][Full Text] [Related]
35. Changes in preoperative characteristics in patients undergoing radical prostatectomy--a 16-year nationwide analysis.
Røder MA; Brasso K; Christensen IJ; Johansen J; Langkilde NC; Hvarness H; Carlsson S; Jakobsen H; Borre M; Iversen P
Acta Oncol; 2014 Mar; 53(3):361-7. PubMed ID: 23957596
[TBL] [Abstract][Full Text] [Related]
36. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
[TBL] [Abstract][Full Text] [Related]
37. 10-Year Mortality After Radical Prostatectomy for Localized Prostate Cancer in the Prostate-specific Antigen Screening Era.
Mendhiratta N; Lee T; Prabhu V; Llukani E; Lepor H
Urology; 2015 Oct; 86(4):783-8. PubMed ID: 26163812
[TBL] [Abstract][Full Text] [Related]
38. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis.
Briganti A; Wiegel T; Joniau S; Cozzarini C; Bianchi M; Sun M; Tombal B; Haustermans K; Budiharto T; Hinkelbein W; Di Muzio N; Karakiewicz PI; Montorsi F; Van Poppel H
Eur Urol; 2012 Sep; 62(3):472-87. PubMed ID: 22633803
[TBL] [Abstract][Full Text] [Related]
39. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
[TBL] [Abstract][Full Text] [Related]
40. Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study.
De Nunzio C; Simone G; Brassetti A; Mastroianni R; Collura D; Muto G; Gallucci M; Tubaro A
BMC Cancer; 2016 Jul; 16():407. PubMed ID: 27386844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
